stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Debt to equity
Xencor, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.0×, down 0.2× from fiscal 2025 (0.2×). Over the past ten years it has ranged from 0.0× (fiscal 2018) to 0.3× (fiscal 2023); the current reading is higher than 82% of that period. That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.2× | (22.37%) |
| FY2024 | 0.2× | (15.20%) |
| FY2023 | 0.3× | 249.02% |
| FY2022 | 0.1× | 77.11% |
| FY2021 | 0.0× | 128.08% |
| FY2020 | 0.0× | 12.15% |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.2× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | 0.0× |
| MBX MBX Biosciences, Inc. compare | 0.0× |
| ADMA ADMA Biologics Inc compare | 0.0× |
| XNCR Xencor, Inc. | 0.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 0.0× |
| PHVS Pharvaris N.V. compare | 0.0× |
| BEAM Beam Therapeutics Inc. compare | 0.1× |
| RCUS Arcus Biosciences, Inc. compare | 0.3× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.4× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement